Hi Wasabi193
Lots of opinions on this.
Alan, Frazis, and many others keep mentioning
- if a company like clarity gets its product developed and on the market, it has failed.
- Big pharma wants to finish their own trials which is why phase 2 is a typical inflection point.
If data flows continue, and they continue to be as spectacular as they have been, big pharma will not want to run second on procuring CU6. It is a company with an early product life cycle and IP protection.
40% mid year
40% by end of year
20% 2025
All guess work and speculation.
Research/Valuation, page-94
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.14 |
Change
0.210(5.34%) |
Mkt cap ! $1.287B | |||
| Open | High | Low | Value | Volume |
| $3.99 | $4.16 | $3.96 | $6.360M | 1.575M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 600 | $4.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.14 | 20088 | 1 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$4.14 |
Change
0.210 ( 5.36 %) |
||||
| Open | High | Low | Volume | ||
| $3.98 | $4.16 | $3.96 | 179425 | ||
| Last updated 15.59pm 17/05/2024 ? | |||||
| CU6 (ASX) Chart |